Antidepressants Flashcards
Discuss risk assessment of acute lithium toxicity
In the setting of normal renal fucntion acute ingestion of <25g is benign causing no more than minor GIT symptoms
Acute ingestion of >25g may cause more singificant GIT symptoms but rarley lead to significant neurotoxicity, provided that good supportive care is instituted so as to avoid dehydration, sodium depletion or renal impairment
Acute or chronic renal impairment of renal function, dehydration or sodium depletion significnatly impairs urinary lithium excretion
If the above are cocurrent with acute ingestion lithium ions are redistribtued to tissue compartments including the CNS instead of being excreted thus enhancing the potential for progressive onset of neurotoxicity
Discuss TK and TM of lithium
TM: Lithium is a monovalent cation primarily used in the management of bipolar disorder. Like most metal salts lithium carbonate acts as a direct irritant to the GI tract. Once absorbed lithium ions substitute for sodium and potassium and ar though to modulate intracellular secondary messengers. They may also affect neuotransmitter poruction and release
TK: Standard release lithium preps are normally completely absorbed within 6 hours of ingestion and peak serum lithium levels occur within 4 hours. Absorption may be prolonged in OD with peak leves delayed up to 12 hours with slow release preparations. Lithium is slowly redistributed from the intravascular compartment to tissue compartments including the CNS with a steady stae volume of 0.7-0.9L/kg. Elimination is almost enterily renal and clearnace is dependant on GFR and reduced in water or sodium deplete states.
Discuss clinal features of acute lithium
Small acute overdoes are often asymptomatic
- Larger overdose show nasuea vomiting abdominal pain and diarrhoea
- significant fluid loss may occur
Neuro
- if they develop they are delayed reflected slow redistribution to the CNS
- Tremor is the earliest sign - rarely progres past this evel as long as ecretion is miantained
- minor ST-T wave changes are observed
Discuss ix of acute lithium ovderose
Standard
EUC
-detect hyponatraemia or renal impairement
LIthium level
- confirm ingestion and monitor progress
- peak levels > 5mmol/L occur are not unusual
Discuss management of acute lithium overdose
Resus
- the patient who present late with severe GI symptoms requires fluid resus aiming for urine output of >1ml/kg/hour - normalisation of NA
- monitor fluid and electrolyte status
- telemtry
D: no indicatied
E: HD is effective however those with normal renal function whose hydration and sodium replacement are ensured benefit littler – reserved for established renal failure or those presenting late with established neuro signs
A: nil
D: - nil evidence of neurotoxicity and serum levels <2.5 can go home
Discuss risk assessment in chronic lithium overdose
Consider lithium intoxication in any pateint on lithium who presents with neurological signs of symptoms
- -signficant obtundation or seizure activity is an indication of severe toxicity that carries risk fo permanent neuro sequale
- serum lithium concentration correlate poorly with clincial feautres
Discuss IX of chornic lithium toxicity
Standard
Serum lithium
-good to confirm diagnosis and monitor paitent preogress
EUC
TFT
Be aware that neurolgoical sequale may persist long after levels return to normal
Discuss clinical features of chronic lithium toxicity
The clinical features are principally neurolgoical. The following classification by Hansen and Amdisen is widely used
Grade 1 (mild)
- tremor, hyperreflexia, agitation, msucle weakness ataxia
Grade 2(moderate)
- stupor, rigidity, hypertonia, hypotension
Grade 3 (severe)
-com, seizures, myclonus
GI symptoms are not prominent with chronic toxicity
The msot common cause of impaired lithium excretion are impaired renal fucntion, diabetes insipidius, sodium depletion, dehydration and drug interaction.
Drugs that impair lithium excretion include
- NSAIDS
- ACE
- Thiazides
- topiramate
Nephrogenic DI and hypothyroidism are associated with lithium tehraepy and can contribute to the development of toxicity and complcate the clinical presentation
Discuss management of chronic lithium toxicity
Resus – not usually required in the absence of siezures.
D: nil
E: HD - considered in patients with neuo dysfunction and a serum lithium level >2.5mmol/L
A: nil
Discuss risk assessement of mirtazapine, TM and TK and managmeent
Deliberate self poisoning with this novel tetracyclic antipdepressant usually follows a benign course with mild CNS depression and tachcardia Care is supportive
TM: mirtazapine is a centrally acting alpha 2 adrenrgic antagonist that enhances release of serotonin and norad. It alos acts as an antagonist at serotonin and histamine receptors
TK: Rapidaly absorbed
85% protein bound with a very large VD >100L/Kg
Hepatic metabolism with renal excretion
Mild tachy, htn and drowsiness may occur
CNS depression is more likley with infgestion of >1000mg but rarely enough to warrent ETT
Treatment is supportive with nil specific decontamination , elimination or antidote
Discuss risk assessment of MAOIs
Irreversible non selective MAO inhibtors are associated with potentially lethal serotonin toxicity in overdose, signficant adverse reaction and a withdrawal syndrome.
Irreversible non slective (phenelzine, tranycyprmine) Irreversible selective (MAO -B) - selegiline Reversible selecrtive (MAO A) moclobemide
Overdose of moclobemide alone causes minor symptoms only irrespective of dose
- non life threatening serotonin syndrome occurs in 5%
- QTc prolongtion >500ms may occur with infgestion >3g but torsades is not reported
- Coingestion with another serotonergic agent is assoicated with higher risk of severe serotonin syndrome
Phenelzine and tranylcypromine are associated with dose dependant potentially lethal serotonin and sympathomimetic toxicity, symptoms are delayed and prolonged
-Dos related risk with phenelzine
->2mg/kg associated with toxicity
-4-6 mg/kg potentially fatal
Dose related asssessment of tranylcypromine
->1mg/kg assocaited with tox
-170mg has caused fatality
CHildren 1-2 of phenelzine or tranycypromine can be associated with signifiacnt toxicity
Discuss TM and TK of MAOi
TM: MAOIs inhibit monoamine oxidase A and B in a selective or non selective reverisble or irreversible manner. MAO-A metabolises serotonin noradrenaline and dopamine. MAO-B metabolises phenylethylamine and benzylamine at central and peripheraln synaptic sites. Irreversible blockade requires new enzyeme synthesis over days to resatblish enzymatic function. Irreversible non selective agents in overdose lead to accumulation of serotonin adrenaline norad doapamine and phenylethylamine resulting in both serotonin and sympathomimetic toxicity that can persist for days
TK: All are well orall absobred with peak levels wihtin 2-3 horus. There is considerable first pass metbaolism. Moderate VD with hepatic metabolism and renal excretion.
Discuss clincial features of MAOI
Moclobemide overdose wihtout ingestion
- minor symptoms
- nausea anxiety and tachycardia may occur
- serotonin syndrome is rare
Phenelzine or tranylcypromine
- usually asymptomatic for the first 6-12 hours
- onset of toxicity is heralded by restlessness, agitation, tachycardia, involunatary movements clonus and hyperreflexia
- rapid decline in conscious state follows
- muscle rigiidy develops leading to resp compromise hypoxia, resp acidosis, hyperthermia and rhabdo
- Autonomic instability is demonstrated by swings from hypo to hypertension
- DIC and MOF may occur
- even with optimal supportive care intoxication may last several days
Classically described MAOI adverse reaction
- serotonin syndrome
- tyramine reaction - after the ingestion of a tyramine containing food (e.g cheese) patients complain of severe occiptal headache, asscoaited with pronounced HTN, sweating, agitation, mydriasis and somtimes chest pain- complications of HTN crises occur
Discuss IX of MAOI
ECG –> prolonged QTC
EUC, FBC, CK, TNI, ABG, CXR, CT head
Discuss management of MAOI od
Resus
- Serotonin syndreome and severe sympathomimetic toxicity are potentially life threatening
-HTN and tachy are usually controlled with titrated IV benzo, severe HTN may require vasodilator therapy - caution is required as the onset of autonomic instability may rapidly produce hypotension
—GTN or SNIP
—Phentolamine 2-3mg increments every 10-15 mintues
Seizure and hyperthermia should be managed
D: patient alert and co-operative with either tranylcypromine or phenelzine are treated with 50g charcoal if present within 2 hours
E: nil
A: cyprohepatadine is indicatated in patient with symptoms consistent with mild to moderate serotonin syndrome
Discuss risk assessment of olanazapine
Olanzapine overdose is associated with predictable does dependant clinical features
- EPS are uncommon
- coingestion of etoh or other sedative hyponotic agents increase the risk fo coma
Dose dependent affect
- <40mg - therapeutic sedation and antipsycotic effect
- 40-100mg mild to moderate sedation with possible anticholinergic effects
- 100-300 sedation with inermittent marked agitation
- > 300mg increased sedation progressive to coma likely to require intubation, hypotension secoandry to peripheral alpha blockade
Discuss TM and TK of olanzapine
TM - antagonist at dopamine (d2), serotonin, histamine, muscarinic and peripheral alpha receptors
TK: - well absorbed orally or sublingually
VD is 10-20L/KG
hepatic metbaolism via CP450
Large first pass effect with oral dosing
Discuss clinical features of olanzapine
Onset of clincal features of intoxication occur within 2-4 hours
- sedation ataxia, miosis, orthostatic hypotnesion and tachycardia are common
- fluctuating mental status with intermittent agitated delirium occurs with moderate doses usually lasting less than 24 hours, Urinary retention frequently complicates this presentation
- Coma when it occurs folloows large ingestions and last from 18-48 horus
- non specific ST-Twave changes occur but clinically signicaint QTC prolongation is rare
- EPS are rare
- Seizrue are rare